An observational study in Metastatic Lung Cancer, Metastatic NSCLC and Metastatic Small Cell Lung Cancer, sponsored by GFPC Investigation. Recruiting at 46 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by GFPC Investigation · Observational
The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment.
Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study.
They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →GFPC Investigation is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients will be recruited by GFPC centers which is a large French network of hospitals and clinics particularly active in pneumology and thoracic oncology centers participating in clinical research.
The principal investigator in each center will identify consecutive patients eligible for inclusion. Patients will be asked to confirm their consent for data collection.
Exclusion Criteria:
Long-term responders defined as patients alive for three years after diagnosis of metastatic Lung cancer (NSCLC and SCLC) and not receiving cytotoxic chemotherapy at the time of inclusion.
Behavioral: Hospital Anxiety and Depression scale (HAD) · Behavioral: Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13) · Behavioral: Questionnaire Aix-Marseille-Université (AMU)
The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to depression (total D), giving two scores (maximum score for each = 21).
The EORTC QLQ-LC13: a 13-item lung cancer-specific questionnaire module supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (cough, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.
Data analysis will be firstly descriptive in order to report on the quality of life of respondents. Then, in a second stage, the factors associated with quality of life will be analyzed using linear or logistic regression models depending on the nature of the variable of interest.
Baseline Clinical Characteristics
Metastatic Lung Cancer Long-Terms Responders clinical characteristics: baseline patient demographics, clinical and pathological characteristics (e.g. age, medical history, comorbidities, past history of cancer, smoking status, NSCLC or SCLC characteristics)
Time frame: At Baseline visit, on a maximum period of 12 months.
Aix-Marseille-University (AMU) questionnaire
Time frame: At inclusion, 6 and 12 months after inclusion and every year up to 5 years
EORTC QLQ-LC13
Time frame: at inclusion, 6 and 12 months after inclusion and every year up to 5 years
Hospital Anxiety and Depression Scale (HAD)
Time frame: at inclusion, 6 and 12 months after inclusion and every year up to 5 years
Treatment characteristics
Treatment characteristics are defined by the type of treatment, the numbers of cycle and the duration of treatment.
Time frame: From date of first lung cancer treatment administration up to 5 years
Health status
Health status will be evaluated using Eastern Cooperative Oncology Group performance status (PS), and collecting data new diseases, cardiovascular, diabetes, second cancers
Time frame: At Baseline visit and up to 5 years
Socio-demographic characteristics
Socio-demographic characteristics will be evaluated based on the following data: professional, socio-family and socio-economic characteristics, education, family status, potential professional exposure(s)
Time frame: At Baseline visit and up to 5 years
Progression free survival (PFS)
PFS is defined as the length of time during and after the treatment of cancer, that a patient lives with the disease but it does not get worse. PFS will be assessed by local review, as per the current practice at site.
Time frame: From date of first lung cancer treatment administration up to 5 years
Overall Survival (OS)
Overall Survival is defined as the length of time from the start of treatment for the cancer that patients diagnosed with the disease are still alive.
Time frame: From date of first lung cancer treatment initiation up to 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GFPC Investigation